论文部分内容阅读
含砷药物在传统中药中用于治疗多种疾病,其中雄黄近年来被用于治疗急性早幼粒细胞白血病,其疗效与三氧化二砷制剂相近,但安全性相对较高。在雄黄纳米微粒诱导的HL-60细胞(人早幼粒白血病细胞)分化早期,细胞内活性氧水平降低p38MAPK抑制剂(SB202190)增强雄黄的诱导分化作用,而线粒体膜通透性转运孔抑制剂(环孢菌素A)减弱雄黄的诱导分化作用。这些实验结果表明,雄黄诱导的HL-60细胞分化与细胞内活性氧水平的降低和线粒体膜通透性转运孔的开放密切相关。该研究为探索含砷抗白血病药物的分子机制提供了新的线索。
Arsenic-containing drugs in the traditional Chinese medicine for the treatment of a variety of diseases, which Realgar in recent years has been used to treat acute promyelocytic leukemia, its efficacy and arsenic trioxide preparations similar, but the safety is relatively high. In the early differentiation of HL-60 cells (human promyelocytic leukemia cells) induced by realgar nanoparticles, the decrease of intracellular reactive oxygen species (p38MAPK) inhibitor (SB202190) enhanced the induction and differentiation of realgar, while the mitochondrial membrane permeability transporter inhibitor (Cyclosporin A) attenuates the induction of differentiation of realgar. These experimental results show that realgar-induced differentiation of HL-60 cells is closely related to the decrease of intracellular reactive oxygen species and the opening of mitochondrial membrane permeability transition pore. This study provides new clues for exploring the molecular mechanism of arsenic-containing anti-leukemia drugs.